ClinicalTrials.gg
CompletedNCT03824405Updated Oct 25, 2022Results posted

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

A Phase 2 interventional study of BTX 1204 and Vehicle in Atopic Dermatitis, sponsored by Botanix Pharmaceuticals. Completed at 31 sites in 3 countries. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-25.

Sponsored by Botanix Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
171st of 544
200 · median 96
Started
2019
with 57 others
Phase 2
202 of 639
18 open now
Registered
312th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 171st largest by enrollment of the 544 interventional ones that give a count, is one of 58 that started in 2019, is one of 202 in phase 2, and was the 312th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.

Read the detailed description

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD. Eligible subjects will be enrolled and randomized to treatment with BTX 1204 or Vehicle for 84 days. Approximately two hundred (200) subjects will be enrolled. Subjects will receive BID application of study drug for 84 days with a final application on the evening of Day 84 for a total of 168 doses.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • CBD
  • Synthetic CBD
  • Cannabidiol
04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is of either gender between 12 and 70 years of age, inclusive.
  2. Subject (or parent/legal guardian) has the ability and willingness to sign a written .
  3. Subject has a diagnosis of chronic (≥1 year), stable atopic dermatitis (AD)
  4. Subject has ≥ 5% and ≤ 30% body surface area (BSA) of AD involvement excluding the scalp and groin.
  5. Subject has an Investigator's Global Assessment (IGA) score of moderate (3) atopic dermatitis on the 5-point IGA (0-4) scale.
  6. For selected photography sites, subject has a target lesion of 25 to 200 cm2 in surface area on the trunk, upper extremities or lower extremities with a Baseline Signs of AD score of ≥ 6 and ≤ 12.
  7. Subject is in good general health without hematological, cardiac, respiratory, renal, endocrine, gastrointestinal, psychiatric, hepatic, or malignant disease, as determined by the investigator.
  8. Subject has suitable venous access for blood sampling.
  9. Subject is able and willing to complete the study and to comply with all study instructions and attend the necessary visits.
  10. Male subjects and their partners must agree and commit to use a barrier method of throughout the study and for 90 days after last study drug application.
  11. A negative urine pregnancy test result for all Women of child bearing potential () at the Screening Visit and Baseline Visit.
  12. Sexually active women must agree to use the following throughout the study and for 30 days after last study drug application. WOCBP who are not sexually active at Baseline and become sexually active must identify a plan for contraception.

    1. One of these highly effective contraception methods Intrauterine device (IUD); hormonal (injections, implants, transdermal patch, vaginal ring); tubal ligation; partner vasectomy, OR
    2. Oral contraceptives WITH a barrier method (listed below), OR
    3. Two barrier forms of contraception (listed below) Male or female condom; diaphragm; cervical cap; contraceptive sponge.
  13. Males subjects must refrain from sperm donation during the study treatment period and until 90 days after last study drug application.

Exclusion criteria

Exclusion Criteria:

  1. Female subject who is breast feeding, pregnant, or planning to become pregnant.
  2. Subject who has an IGA score of 2 (mild) or 4 (severe).
  3. Subject with history of known or suspected intolerance to the drug product .
  4. Subject has any active infection in the investigator's opinion. This includes active impetigo at any AD lesion.
  5. Subject has known Hepatitis-B, Hepatitis-C, or infection.
  6. Subject has excessive body or facial hair that would interfere with the evaluation of safety or with the diagnosis or assessment of AD.
  7. Subject has sunburns, unevenness in skin tones, tattoos, scars, excessive hair, freckles, birthmarks, moles, or other skin damage or abnormality that would result in the inability to evaluate the AD lesions.
  8. Subject has clinically significant or severe allergies that in the investigator's opinion would interfere with participation in the study.
  9. Subject has known intolerability to topical treatments e.g., reports excessive burning/stinging or pain with use of topical treatments.
  10. Subject has an active or potentially recurring skin conditions(s) other than AD that in the investigator's opinion would interfere with participation in the study.
  11. Subject has unstable AD consistent with a requirement for high-potency .
  12. Subject has used dupilumab (Dupixent) within 12 weeks prior to the Baseline Visit.
  13. Subject has used any biologic therapy, other than dupilumab, within 28 days prior to the Baseline Visit.
  14. Subject has used systemic (oral, IV or IM) corticosteroids within 28 days prior to the Baseline Visit. Intra-articular injection for arthroses allowed.
  15. Subject has used topical anti-pruritics (e.g., PDE4 inhibitors) within 28 days prior to the Baseline Visit.
  16. If subject is taking oral antihistamines, subject has not been on a stable dose of oral antihistamines within 28 days prior to the Baseline visit.
  17. Subject has used phototherapy, tanning beds, or any other artificial light device within 28 days prior to the Baseline Visit.
  18. Subject has used topical corticosteroids within 14 days prior to the Baseline Visit.
  19. Subject has used topical calcineurin inhibitors within 14 days prior to the Baseline Visit.
  20. Subjects has used barrier creams (e.g., Mimyx, Atopiclair), within 7 days prior to the Baseline Visit.
  21. Subject has an underlying disease that requires the use of interfering topical or systemic therapy.
  22. Subject has other dermatological conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, acne or rosacea.
  23. Subject has a clinically relevant history or currently suffering from any disease or condition that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk or interfere with the subject's participation in the study. Subjects with other dermatologic conditions, including genetic syndromes that have an eczematous dermatitis as a component of the disease (e.g., Netherton's) are excluded.
  24. Subject has a clinically relevant history of or current evidence of abuse of alcohol or other drugs.
  25. Subject is currently using any medication that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk.
  26. Subject has participated in another drug or device research study within 30 days of the Screening Visit or five half-lives of the drug, whichever is longer.
  27. Any other reason that would make the subject, in the opinion of the Investigator or sponsor, unsuitable for the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    BTX 1204

    BTX 1204 twice daily

    Drug: BTX 1204

  • Placebo comparator
    Vehicle

    Vehicle twice daily

    Drug: Vehicle

Interventions

  • BTX 1204 liquid formulation

  • DrugVehicle

    Vehicle liquid formulation

06

What researchers measure

Primary outcomes

  1. Investigator's Global Assessment (IGA)

    Investigator's Global Assessment (IGA) success defined as an IGA score of "Clear" (0) or "Almost Clear" (1) with at least a 2-grade improvement

    Time frame: Day 85

07

Results

Posted Sep 27, 2022

Participant flow

Participant flow — Overall Study
MilestoneBTX 1204Vehicle
Started100100
Completed6555
Not completed3545

Outcome measures

PrimaryInvestigator's Global Assessment (IGA)

Investigator's Global Assessment (IGA) success defined as an IGA score of "Clear" (0) or "Almost Clear" (1) with at least a 2-grade improvement

Time frame:
Day 85
Reported as:
Count of participants · Participants
Investigator's Global Assessment (IGA)
ParticipantsBTX 1204Vehicle
Success1218
Failure8777

Adverse events

Collected over 85 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BTX 12040/99 (0%)2/99 (2%)37/99 (37.4%)
Vehicle0/98 (0%)0/98 (0%)25/98 (25.5%)
Most frequent serious events
Most frequent serious events
EventBTX 1204Vehicle
Post-procedural complicationGeneral disorders1/990/98
PneumoniaRespiratory, thoracic and mediastinal disorders1/990/98
Most frequent other events
Most frequent other events
EventBTX 1204Vehicle
Dermatitis atopicSkin and subcutaneous tissue disorders11/9915/98
ErythemaSkin and subcutaneous tissue disorders7/991/98
NasopharyngitisSkin and subcutaneous tissue disorders6/991/98
Application Site PainSkin and subcutaneous tissue disorders4/992/98
PruritisSkin and subcutaneous tissue disorders3/993/98
Application Site ReactionSkin and subcutaneous tissue disorders3/992/98
Dry SkinSkin and subcutaneous tissue disorders3/991/98

Baseline characteristics

Intent-to-treat Population

Age, Categorical
Age, Categorical(Participants)BTX 1204VehicleTotal
<=18 years201535
Between 18 and 65 years7776153
>=65 years246
Sex: Female, Male
Sex: Female, Male(Participants)BTX 1204VehicleTotal
Female6254116
Male374178
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BTX 1204VehicleTotal
Hispanic or Latino91120
Not Hispanic or Latino9084174
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BTX 1204VehicleTotal
American Indian or Alaska Native101
Asian181735
Native Hawaiian or Other Pacific Islander224
Black or African American141832
White5355108
More than one race11314
Unknown or Not Reported000
Investigator Global Assessment
Investigator Global Assessment(Participants)BTX 1204VehicleTotal
0 - Clear000
1 - Almost Clear000
2 - Mild000
3 - Moderate9995194
4 - Severe000
08

Study locations

31 sites
  • Applied Research Center of Arkansas Inc.
    Little Rock, Arkansas 72212, United States
  • T. Joseph Raoff MD Inc. / Encino Research Center
    Encino, California 91436, United States
  • Center for Dermatology Clinical Research
    Fremont, California 94538, United States
  • Dermatology Specialist Inc. - Murrieta
    Murrieta, California 92562, United States
  • Rady Childern's Hospital - San Diego
    San Diego, California 92123, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Precision Clinical Research
    Davie, Florida 33328, United States
  • Troy Sullivan
    North Miami Beach, Florida 33162, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Delright Research
    New Orleans, Louisiana 70115, United States
  • Medisearch Clinical Trails
    Saint Joseph, Missouri 64506, United States
  • Washington Univerisy in St. Louis
    Saint Louis, Missouri 63141, United States
  • JDR Dermatology Research LLC
    Las Vegas, Nevada 89148, United States
  • The Acne Treatment and Research Center
    Morristown, New Jersey 07960, United States
  • Aventiv Research Inc - Dublin
    Dublin, Ohio 43016, United States
  • Greenville Dermatology, LLC
    Greenville, South Carolina 29607, United States
  • Dermresearch Inc
    Austin, Texas 78759, United States
  • J&S Studies Inc.
    College Station, Texas 77845, United States
  • The Center for Skin Research at Suzanne Bruce & Associates Dermatology
    Houston, Texas 77056, United States
  • CMAX Clincial Research
    Adelaide, 5000, Australia
  • BurwoodDermatology
    Burwood, 6100, Australia
  • Sinclair Dermatology
    East Melbourne, 3002, Australia
  • North Eastern Health Specialists
    Hectorville, 5073, Australia
  • Premier Specialists PTY LTD
    Kogarah, 2217, Australia
  • St George Dermatology & Skin Cancer Center
    Kogarah, 2217, Australia
  • Captain Stirling Medical Centre
    Nedlands, 6009, Australia
  • The Skin Hospital
    Westmead, 2145, Australia
  • Veracity Clinical Research
    Woolloongabba, 4102, Australia
  • Optimal Clinical Trials
    Auckland, 1010, New Zealand
  • Clinical Trials New Zealand LTD
    Hamilton, 3204, New Zealand
  • P3 Research
    Wellington, 6021, New Zealand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jan 2020, 11 months.

Results were first posted in Sep 2022, 2 years 8 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 11 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Jan 31, 2019
StartActual
Feb 4, 2019
Primary completionActual
Jan 27, 2020
CompletionActual
Mar 4, 2020
Results first posted
Sep 27, 2022
Last update
Oct 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03824405
Lead sponsor
Botanix Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 31, 2019
Start date
Feb 4, 2019
Primary completion
Jan 27, 2020
Completion
Mar 4, 2020
Results posted
Sep 27, 2022
Last update
Oct 25, 2022

Study contacts

Anthony Robinson, CRNP
study director · Head of Development, Botanix Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion